Arafura Rare Earths (ASX: ARU) is trading near a key support zone after recent volatility, where buyers have previously stepped in. Strength in rare earth prices adds sector momentum. While this mix may signal opportunity, confirmation depends on support holding and the company delivering meaningful project progress.
European Lithium (ASX: EUR) hit its target price after a high-volume breakout from consolidation, rallying to A$0.39. A proposed US$835M acquisition by Critical Metals Corp and renewed interest in its lithium and rare earth assets drove the surge.
1414 Degrees is an ASX-listed cleantech company developing silicon-based thermal storage, hydrogen and battery materials; investor interest reflects Aurora and SiNTL progress, fresh $2.69 million funding, and a high-volume share-price breakout that now needs follow-through.
Liontown Resources (ASX: LTR) is a next-generation lithium developer advancing toward production at its flagship Kathleen Valley Project in Western Australia. With Tier-1 offtake partners and strong financial backing, Liontown is poised to become a key player in the global EV and battery supply chain.
Larvotto Resources Limited (ASX: LRV) is an Australian emerging mining company transitioning from explorer to near-term producer. Its flagship asset, the Hillgrove Antimony–Gold Project in New South Wales, positions the company as a potential supplier of two strategically important metals: gold—a monetary safe-haven—and antimony, a critical mineral used in batteries, semiconductors, and defense alloys.
Racura Oncology (ASX: RAC) is executing on a bold clinical strategy centered on RC220 (bisantrene reformulation), targeting both cardioprotection and enhanced anticancer activity in combination with doxorubicin. The company has dosed its first patient in a Phase 1 solid tumor trial, expanded into South Korea, and strengthened its clinical leadership team, all while maintaining disciplined cash management (A$13.67m at June 2025) to fund operations into 2026. Though early-stage, RAC presents a compelling mid- to long-term optionality scenario for investors with conviction in cardio-oncology and specialty chemotherapy.
...
